Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Author(s):
Weinblatt, M.E.; Fleischmann, R.; Vollenhoven, R.F. van; Emery, P.; Huizinga, T.W.J. (0000-0001-7033-7520); Cutolo, M.; Heijde, D. van der; Duncan, B.; Davies, O.; Luijtens, K.; Dougados, M.
